Profil
Lisa M.
Bell worked as a Senior Director-Regulatory & Safety at Abbott Biotherapeutics Corp.
and as the Head-Regulatory & Pharmacovigilance at BioMarin Pharmaceutical, Inc. She was also the Senior Vice President- Global Regulatory Affairs at Coherus BioSciences, Inc. from 2014 to 2017.
Bell received her undergraduate and graduate degrees from Boston University and her doctorate from the University of California, Berkeley.
Ehemalige bekannte Positionen von Lisa M. Bell
| Unternehmen | Position | Ende |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | General Counsel | 01.12.2017 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | General Counsel | - |
| BIOMARIN PHARMACEUTICAL INC. | General Counsel | - |
Ausbildung von Lisa M. Bell
| University of California, Berkeley | Doctorate Degree |
| Boston University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| COHERUS BIOSCIENCES, INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
